Showing 20 of 102 recruiting trials for “perihilar-cholangiocarcinoma”
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
👨⚕️ Jason Molitoris, MD, PhD, University of Maryland Medical Center / Maryland Proton Treatment Center📍 2 sites📅 Started Oct 2024View details ↗
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
RecruitingNCT06648057 ↗
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
🏥 The First Affiliated Hospital with Nanjing Medical University📍 4 sites📅 Started Sep 2024View details ↗
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
RecruitingNCT06718257 ↗
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
👨⚕️ Weilin Wang, PHD, Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT07101237 ↗
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
RecruitingNCT07291063 ↗
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
👨⚕️ Hop S Tran Cao, University of Texas MD Anderson Cancer Center LAO📍 58 sites📅 Started Jul 2024View details ↗
RecruitingNCT06505486 ↗
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
👨⚕️ Jia-yan Ni, M.D., Sun Yat-sem Memorial Hospital, Sun Yat-sen University📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06643208 ↗
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
👨⚕️ Maolin Yan, Doctor, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital📍 1 site📅 Started Jul 2024View details ↗
Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma
👨⚕️ Alejandra Méndez Romero, MD, PhD, Erasmus Medical Center📍 8 sites📅 Started Jul 2024View details ↗
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →